The phase 3 IRAKLIA trial found that subcutaneous isatuximab delivered via an on-body system was as effective and safe as intravenous (IV) administration in relapsed/refractory multiple myeloma, ...

Dr. Charles, Accomplished Immunology-Focused Drug Developer, Brings More Than 20 years of Biopharma Leadership, Clinical ...

Immunoglobulin A nephropathy (IgAN), or Berger’s disease, is a chronic kidney disorder characterized by deposition of IgA antibodies in the glomeruli, which leads to inflammation and progressive renal ...

In cancer care, accurate tools for predicting whether a tumor will spread (metastasize) can help patients receive the most ...

Presented as one of the top 10 abstracts at the ERA Congress 2025, the study analysed urine samples from 247 biopsy-confirmed IgA nephropathy patients alongside 50 healthy controls. Researchers ...

Epimab Biotherapeutics Inc. licensed out a development-ready KLK2/CD3 bispecific T-cell engager (TCE) for advanced prostate cancer to Juri Biosciences Inc. through a potential $210 million deal.

Iga Swiatek continued her torrid run through the French Open by dispatching Elina Svitolina on Tuesday to set up a semifinal encounter against top-ranked Aryna Sabalenka.

Tissue samples from 54 additional patients at various BOS stages were also evaluated for polymeric Ig receptor (pIgR) expression and subepithelial IgA-producing B-cell presence. S-IgA levels in BALF ...

A Texas A&M University professor has inked America’s first ever agreement for medical clinical trials with Saudi Arabia, advancing research on potentially groundbreaking cell therapies.